Biomarker disclosure protocols in prodromal Alzheimer's disease clinical trials.

ABSTRACT:

Introduction

The development of biomarkers for Alzheimer's disease (AD) has allowed researchers to increase sample homogeneity and test candidate treatments earlier in the disease. The integration of biomarker "screening" criteria should be met with a parallel implementation of standardized methods to disclose biomarker testing results to research participants; however, the extent to which protocolized disclosure occurs in trials is unknown.

Methods

We reviewed the literature to identify prodromal AD trials published in the past 10 years. From these, we quantified the frequency of biomarker disclosure reporting and the depth of descriptions provided.

Results

Of 30 published trials using positron emission tomography or cerebrospinal fluid-based amyloid positivity as an

SUBMITTER: Rahman-Filipiak A 

PROVIDER: S-EPMC10530125 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature